Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial HEPATOLOGY Wyles, D., Poordad, F., Wang, S., Alric, L., Felizarta, F., Kwo, P. Y., Maliakkal, B., Agarwal, K., Hassanein, T., Weilert, F., Lee, S. S., Kort, J., Lovell, S. S., Liu, R., Lin, C., Pilot-Matias, T., Krishnan, P., Mensa, F. J. 2018; 67 (2): 514–23
View details for DOI 10.1002/hep.29541
View details for Web of Science ID 000422694900010